Posted: 05/08/2025 07:59 am
Artivion, Inc. (NYSE: AORT), a prominent player in the cardiac and vascular surgery industry with a focus on aortic disease, has recently offered a glimpse into its executive compensation landscape through its public financial documents. At the heart of these disclosures is Lance Berry, the Executive Vice President and Chief Financial Officer, whose total compensation for the year 2024 totaled $2,574,033. This package comprises a base salary of $500,000, an incentive plan compensation of $390,000, and a considerable stock award totaling $1,499,980, further rounded out by $184,053 in other forms of compensation.^1
This compensation compares with previous years, notably D. Ashley Lee, who served as Executive Vice President and Chief Financial Officer in 2022 with a stock award amounting to $888,884 and total compensation of $2,330,212.^2 Such figures highlight Artivion's emphasis on leveraging stock awards as a key component of rewarding its executive leadership, reflecting both a method of aligning executive interests with shareholder value and a competitive approach to retaining top talent within the surgical and medical instruments industry.
Beyond individual compensation, Artivion's financial journey through the first quarter of 2025 reflects a mix of achievements and challenges. Despite a 2% increase in revenue, totaling $99 million, Artivion reported a quarterly net loss of $0.5 million. While this was counterbalanced by a non-GAAP net income of $2.5 million, earnings per share were reported at $0.06, which fell short of the Zacks Consensus Estimate of $0.12.^3 This shortfall reflects a demanding operational environment, despite consistent strategic advances, such as the submission of a pre-market approval application to the FDA for the AMDS Hybrid Prosthesis.^4
The company's stock performance echoes this nuanced outlook, showing a recent 3.5% increase in price with shares trading at $28.38, positioning close to the higher end of the year’s range.^5 This boost in stock performance comes amidst Artivion's efforts to stabilize and grow post-cybersecurity incident and several strategic initiatives, as evidenced by recent trials and FDA submissions.^6^7
Through these developments, Artivion maintains its commitment to a path of innovation in tackling aortic diseases. The company's recent data presentations, like those from the AMDS PERSEVERE Trial, provide critical insights into its clinical advances and sustained benefits in surgical outcomes, adding clinical credibility and support to its financial and strategic aspirations.^8^9
In summary, Artivion stands at the intersection of strategic transition and executive compensation dynamics as it adapts to evolving challenges and opportunities in the medical technology sector. By rewarding its executives with substantial stock-based incentives and pursuing robust clinical trials, Artivion looks to cement its competitive edge while navigating the financial intricacies that define the healthcare space.
---
1. U.S. Securities and Exchange Commission. [2024 Compensation of Lance A. Berry](https://www.sec.gov/Archives/edgar/data/784199/000199937125003629/0001999371-25-003629-index.htm).
2. U.S. Securities and Exchange Commission. [2022 Compensation of D. Ashley Lee](https://www.sec.gov/Archives/edgar/data/784199/000199937124004301/0001999371-24-004301-index.htm).
3. Zacks. [Artivion (AORT) Lags Q1 Earnings Estimates](https://www.zacks.com/stock/news/2462503/artivion-aort-lags-q1-earnings-estimates).
4. PRNewswire. [Artivion Reports First Quarter 2025 Financial Results](https://www.prnewswire.com/news-releases/artivion-reports-first-quarter-2025-financial-results-302446214.html).
5. Daily snapshot of Artivion, Inc. stock price.
6. Zacks. [Strength Seen in Artivion (AORT)](https://www.zacks.com/stock/news/2443253/strength-seen-in-artivion-aort-can-its-7-9-jump-turn-into-more-strength).
7. Seeking Alpha. [Artivion, Inc. Q1 2025 Earnings Call Transcript](https://seekingalpha.com/article/4782012-artivion-inc-aort-q1-2025-earnings-call-transcript).
8. PRNewswire. [Artivion Announces Presentation of New Clinical Data](https://www.prnewswire.com/news-releases/artivion-announces-presentation-of-new-clinical-data-from-nexus-triomphe-ide-trial-at-the-105th-american-association-for-thoracic-surgery-aats-annual-meeting-302445689.html).
9. PRNewswire. [Artivion Announces Presentation of Late-Breaking Data](https://www.prnewswire.com/news-releases/artivion-announces-presentation-of-late-breaking-data-from-amds-persevere-trial-at-the-61st-society-of-thoracic-surgery-annual-meeting-301756321.html).
